The AACR blockbuster RATIONALE-304: Clinical study of tumor mutational burden (TMB) versus tislelizumab (TIS) + chemotherapy (chemo) versus chemotherapy alone in the first-line treatment of advanced non-squamous non-small cell lung cancer (nsq-NSCLC) outcome study

In a previous analysis of the RATIONALE-304 (NCT03663205) trial, tislelizumab (TIS) plus platinum-based chemotherapy significantly improved clinical outcomes over chemotherapy alone in treatment-resistant advanced nsq- NSCLC (by IRC).

In a previous analysis of the RATIONALE-304 (NCT03663205) trial, tislelizumab (TIS) plus platinum-based chemotherapy significantly improved clinical outcomes over chemotherapy alone in treatment-resistant advanced nsq- NSCLC (by IRC).

Recently, the RATIONALE-304 study, led by Shanghai Chest Hospital, reported at AACR biomarker analysis of baseline tissue and blood TMB (tTMB and bTMB, respectively)

Patients with nsq-NSCLC were randomly assigned in a 2:1 ratio to TIS+platinum+pemetrexed or platinum+pemetrexed

Patients with nsq-NSCLC were randomly assigned in a 2:1 ratio to TIS+platinum+pemetrexed or platinum+pemetrexed

RESULTS: Of the 325 RATIONALE-304-treated patients without EGFR sensitizing mutations, 177 (54.

The relationship between TMB and TIS + chemotherapy and PFS benefit of chemotherapy

Taken together, in this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting that tTMB and bTMB have limited clinical utility in the setting of TIS+chemotherapy as first-line treatment for advanced nsq-NSCLC

Taken together, in this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting that tTMB and bTMB have limited clinical utility in the setting of TIS+chemotherapy as first-line treatment for advanced nsq-NSCLC

source:

source:

https://#!/10517/presentation/19967

https://#!/10517/presentation/19967 https://#!/10517/presentation/19967

Leave a comment here